Webinar | How growing biopharma companies can avoid the commercial fragmentation trap

As biopharma companies grow and add new products, indications, markets, and data sources, their commercial systems can fragment faster than they scale.

Data, technology, and decision logic multiply across teams until everything is moving but nothing is moving together. Signals, assumptions, and business rules become scattered across point solutions, spreadsheets, and teams.

A change in market understanding may inform one function but fail to carry through to targeting, field execution, incentive compensation, market access, patient support, and measurement.

AI raises the stakes. It can surface signals and recommendations faster, but if the underlying data, decision logic, and workflows remain fragmented, those outputs become harder to validate, trust, and act on.

The speakers will discuss how growing companies determine how to evolve technology and systems pragmatically without a large-pharma transformation.

They’ll discuss how companies are:

- Keeping commercial decisions and execution aligned across functions as the market and business change

- Scaling across products and markets without repeated rebuilds by reusing data, decision logic, and workflows

- Bringing analytics and AI into day-to-day workflows so insights can support more coordinated action

- Sequencing investments based on business need, system dependencies, and implementation complexity

Turning investments into real patient impact: Lessons from consumer-oriented and specialty Rx brands

Patient centricity means very different things depending on the brand. For consumer-oriented products, it often shows up as reach, relevance, and sustained engagement at scale. For specialty and complex therapies, it’s about precision, access, and navigating a complex patient journey. Yet across both, teams are grappling with the same challenge: how to turn data, AI, and technology investments into real patient impact, without losing trust or cohesion along the way.